Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal

Group 1 - Sangamo Therapeutics, Inc. (NASDAQ: SGMO) has established a deal with Eli Lilly and Company (LLY) to advance up to 5 neurological programs [2] - The article is authored by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace, providing in-depth analysis of pharmaceutical companies [1][2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2]